That is not $30 million it is about $28.3 million after the cut and 2.2 million shares sold at $1.50 discount. The way rich, crooked and connected work. They really do not need this money.
I am not sure if they needed those $28.3 Million dollars. Just my opinion- backdoor entry for rich and connected.
I saw that plan of Trumph: More trickle down economics and he is going to take care of middle class people. But some do not vote for their economic interests but then cry when the world passing them by.
J&E adds a lot to the nuances of this science.
Chinaman, is a fun guy to have on any board.
James and Reilly are two other guys I respect a lot here.
All others LTSH are my MB buds- we are all sailing in this together.
I did not put out what can also be possible:
When you use LmLLO- other markers of T cell activation (either suppressors or stimulators) may be expressed- which in each individual or with each different malignancy may be different and PD1/PDL1 markers may
be one of the many which can be exploited.
Now that sounds better! Let me know but THANKS.
I have an ex-Chemical Engineering Prof. from Georgia Tech as a friend- he always said the laggards in Chemical Engineering went to old BP companies. That trial by BMS does make me believe he may be right.
BMS tried to out beat Merck with results from lung cancer study. Merck got approval
For lung cancer with 50% expression of PD1/PDL1 (T Cell/Tumor Cell). They looked at
Those with more than 5% expression. But the assay to detect is not a reliable one and the is less reliable when the expression is low. They lost $4 billion but they do not care because they can soak it to US Healthcare System- these type of mistakes is they happened in Public Institutions will raise hell. They also picked second rate bioengineered ADRO vs the gem “Advaxis” platform.
The good news is there are many competitors in PD1/PDL1 Space:
These include Merck, AZN, PFE, Merch Serono (German) and Roche.
Let's see who does their homework better and picks Advaxis over ADRO.
Forbes had an article why this BMS disaster is a win for personalized cancer immunotherapy- an AMGN made a smart move before anybody could get it.
Folks (esp. LTSH) now hold on to your shares.
If you look at health care costs esp. drug prices which is going to make healthcare unaffordable-
look no further then Advaxis in Biotech. Rest of the industry - the cost of biotech medications have to come down at least in US and if they can balance by increasing costs elsewhere.
BMS would need ADXS- because LmLLO treatment can help express PD1 or PDL1 on tumor or host immune cells and can help Opdivo to be used. Not the other way around. They need us.
That means Advaxis is expanding its partners and reliance on Merck is down:
Do you think some of it the sames guys selling and buyin? Not many traders here. LTSH are holding on. Maybe institutions trying to can more- dump a few and buy more?.
There is a poster on AVXL- dadofmarx- a neurologist. See and follow him. He advised people to buy more under $5. I am waiting to see how it turns. May dip in and buy more of AVXL.